Danaher Corporation (DHR)
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreKey Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Mr. Steven M. Rales
|
Co-Founder & Chairman | -- | -- | 1951 |
|
Ms. Julie Sawyer Montgomery
|
President, CEO & Director | 2.58M | -- | 1972 |
|
Mr. Mitchell P. Rales
|
Co-Founder & Director | -- | -- | 1957 |
|
Dr. Jose-Carlos Gutierrez-Ramos Ph.D.
|
Senior VP & Chief Science Officer | 2.52M | -- | 1962 |
|
Mr. Matthew R. McGrew
|
Executive Vice President | 3.17M | 2.45M | 1972 |
|
Mr. Rainer M. Blair
|
Senior Advisor | 6.12M | -- | 1964 |
|
Mr. Christopher Paul Riley
|
Executive VP of Biotechnology Group & CEO of Cytiva | 2.54M | 947.66k | 1974 |
|
Mr. Matthew E. Gugino C.F.A., CPA
|
Executive VP & CFO | -- | -- | 1983 |
|
Mr. Christopher M. Bouda
|
VP & Chief Accounting Officer | -- | -- | -- |
|
Ms. Rachel Marie Vatnsdal Olson
|
Vice President of Investor Relations | -- | -- | -- |
Danaher Corporation
- Sector:
- Healthcare
- Industry: Diagnostics & Research
- Full Time Employees:
- 58,000
Description
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands. The Diagnostics segment offers clinical instruments, consumables, software, and services that hospitals, physicians' offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was incorporated in 1969 and is headquartered in Washington, the District Of Columbia.
Corporate Governance
Upcoming Events
October 21, 2026 at 12:30 PM UTC
Danaher Corporation Earnings Date
October 30, 2026 at 12:00 AM UTC
Dividend Date
Recent Events
September 30, 2026 at 12:00 AM UTC
25-NSE: Notification filed by national security exchange to report the removal from listing and registration of matured
September 30, 2026 at 12:00 AM UTC
Ex-Dividend Date
May 12, 2026 at 12:00 AM UTC
SD: Specialized Disclosure Report filed pursuant to Section 1502 of the Dodd-Frank Wall Street Reform and Consumer Protection Act relating to the use of conflict minerals (Rule 13p-1)
